financetom
Business
financetom
/
Business
/
Asure Software Q4 Loss Narrows, Revenue Rises; 2025 Outlook Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Asure Software Q4 Loss Narrows, Revenue Rises; 2025 Outlook Reaffirmed
Mar 6, 2025 1:36 PM

04:18 PM EST, 03/06/2025 (MT Newswires) -- Asure Software ( ASUR ) posted a Q4 diluted loss late Thursday of $0.12 per share, narrowing from a loss of $0.14 a year earlier.

Analysts polled by FactSet expected a loss of $0.06.

Revenue for the quarter ended Dec. 31 was $30.8 million, up from $26.3 million a year earlier.

Analysts surveyed by FactSet expected $30.8 million.

The company said it expects Q1 revenue of $33 million to $35 million. Analysts polled by FactSet expect $35.4 million.

Asure continues to expect full-year 2025 revenue of $134 million to $138 million. Analysts polled by FactSet expect $134.7 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dolby Laboratories Insider Sold Shares Worth $841,908, According to a Recent SEC Filing
Dolby Laboratories Insider Sold Shares Worth $841,908, According to a Recent SEC Filing
Nov 27, 2024
04:52 PM EST, 11/27/2024 (MT Newswires) -- Ryan Nicholson, Vice President, Chief Accounting Officer and Corporate Controller, on November 26, 2024, sold 10,500 shares in Dolby Laboratories ( DLB ) for $841,908. Following the Form 4 filing with the SEC, Nicholson has control over a total of 24,364 shares of the company, with 24,364 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1308547/000095017024131570/xslF345X05/ownership.xml...
Marker Therapeutics Files $300 Million Mixed Shelf
Marker Therapeutics Files $300 Million Mixed Shelf
Nov 27, 2024
04:51 PM EST, 11/27/2024 (MT Newswires) -- Marker Therapeutics ( MRKR ) filed a registration statement Wednesday for the potential sale of up to $300 million of securities from time to time in one or more offerings. The filing covers the sale of the company's common and preferred shares, debt securities and warrants. Proceeds from the offering will be used...
US FDA Rejects Applied Therapeutics' New Drug Application for Govorestat in Classic Galactosemia
US FDA Rejects Applied Therapeutics' New Drug Application for Govorestat in Classic Galactosemia
Nov 27, 2024
04:51 PM EST, 11/27/2024 (MT Newswires) -- Applied Therapeutics ( APLT ) said late Wednesday that the US Food and Drug Administration issued a complete response letter indicating the health regulator's decision not to approve the new drug application for govorestat to treat classic galactosemia due to deficiencies in the clinical application. The drugmaker said it is reviewing the regulator's...
Upstart Holdings Insider Sold Shares Worth $4,463,815, According to a Recent SEC Filing
Upstart Holdings Insider Sold Shares Worth $4,463,815, According to a Recent SEC Filing
Nov 27, 2024
04:53 PM EST, 11/27/2024 (MT Newswires) -- Paul Gu, Director, Chief Technology Offier, on November 25, 2024, sold 58,786 shares in Upstart Holdings ( UPST ) for $4,463,815. Following the Form 4 filing with the SEC, Gu has control over a total of 863,065 shares of the company, with 863,065 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1647639/000162828024049410/xslF345X05/wk-form4_1732744022.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved